Extended Data Fig. 10: Pharmacological inhibition of KDM6B attenuates tumor growth and causes pro-inflammatory skewing of the TME.
From: Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade
a, Representative axial MRI images of CT-2A tumor from vehicle treated mice (left panel) and GSK-J4 treated mice (right panel), taken on day 14 post tumor inoculation. b, Box and whisker plot showing the difference in CT-2A tumor volumes (determined from MRI) between vehicle and GSK-J4 treated mice (n = 10 female mice/group). Two-tailed Student’s t-test was performed. Whiskers represent minimum to maximum values. c, Box and whisker plot depicting the difference in CT-2A tumor weight (harvested on day 22 post tumor inoculation) between vehicle and GSK-J4 treated mice (n = 10 female mice/group). Two-tailed Student’s t-test was performed. Whiskers represent minimum to maximum values. d, Heatmap demonstrating the expression of protein markers of interest in the indicated CD45+ immune cell clusters in the GBM (CT-2A) TME of vehicle & GSK-J4 treated mice as determined by mass cytometry. e, Heatmap showing the expression of protein markers of interest in the indicated CD45+ immune cell clusters as determined by mass cytometry (shown in Fig. 7j).
